Dr. David Weisman
Claim this profileAbington Neurological Associates
Expert in Alzheimer's Disease
Studies Dementia
14 reported clinical trials
18 drugs studied
Area of expertise
1Alzheimer's Disease
Global Leaderdonanemab
ApoE positive
ApoE negative
2Dementia
donanemab
Affiliated Hospitals
Clinical Trials David Weisman is currently running
CT1812
for Early Alzheimer's Disease
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.
Recruiting0 awards Phase 2
Ofatumumab
for Multiple Sclerosis
The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study. Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS).
Recruiting2 awards Phase 3
More about David Weisman
Clinical Trial Related1 year of experience running clinical trials · Led 14 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments David Weisman has experience with
- Placebo
- Donanemab
- Aducanumab
- ALZ-801
- APT Webstudy
- Escitalopram
Breakdown of trials David Weisman has run
Alzheimer's Disease
Dementia
Mild Cognitive Impairment
Cognitive Impairment
Psychomotor Agitation
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David Weisman specialize in?
David Weisman focuses on Alzheimer's Disease and Dementia. In particular, much of their work with Alzheimer's Disease has involved donanemab patients, or patients who are ApoE positive.
Is David Weisman currently recruiting for clinical trials?
Yes, David Weisman is currently recruiting for 3 clinical trials in Abington Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that David Weisman has studied deeply?
Yes, David Weisman has studied treatments such as Placebo, Donanemab, Aducanumab.
What is the best way to schedule an appointment with David Weisman?
Apply for one of the trials that David Weisman is conducting.
What is the office address of David Weisman?
The office of David Weisman is located at: Abington Neurological Associates, Abington, Pennsylvania 19001 United States. This is the address for their practice at the Abington Neurological Associates.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.